CD4 Therapeutics

CD4 Therapeutics is a private, clinical-stage biotech pioneering Treg-activating therapies, with Tregalizumab as its lead candidate. The company secured exclusive worldwide rights to Tregalizumab in July 2024 and is targeting fast-track development in high-need, orphan-designation indications. With a lean strategy, strong IP, and a leadership team boasting decades of industry experience, CD4 positions itself as a de-risked investment opportunity in the rapidly expanding autoimmune therapeutics market.

Monoclonal antibody platform for selective activation of regulatory T-cells (Tregs) to restore immune tolerance.

Claims no direct competitors with an approved Treg-activating monoclonal antibody. However, faces indirect competition from broad immunosuppressants, targeted biologics, and other emerging immunomodulatory approaches in autoimmune diseases. The field of Treg-based therapies is growing, including adoptive cell therapies.